AGMFor anyone truly interested in the Company, the AGM is June 27, Fairmont Royal York, 10am. In the circular Brydon & Rossi say it is not past achievements that truly excite them. "What motivates and drives us forward with passion and conviction are the prospects that lie ahead as our business continues to evolve." They speak of "expected transformational events" and "great confidence" going forward.
Interesting to note in the circular that after the financing, First Generation Capital owns 21.7 million shares and West-Face Capital owns 18.7 million shares - for a total of 40.5 million shares (27.3%) between the two funds. These are aggressive funds that invest for one reason - to make money.
Compleo TRT is a potential company maker on its own and will lead the short term success of Trimel; Tefina provides speculative spice. There are not that many $ multi-billion drug opportunities out there but T-Replacement is definitely one of them.
Listen up, young men - apparently not just normal age demographics are affecting demand for T Replacement. "A generational drop in testosterone has been observed. Twenty years go, men of all ages had higher testosterone levels than their counterparts today, meaning an average 50 year old guy in 1993 had higher testosterone than an average 50 year old guy in 2013. Something other than aging is lowering testosterone across the board. This shows that T production is subject to other factors, not just aging. A recent study found that the “age-related” declinations in testosterone were modified by body weight changes and other lifestyle factors. As body weight went up, T went down. As body weight went down, T went up. ... Another study found that metabolic syndrome exacerbates testosterone deficiency." https://www.marksdailyapple.com/the-inevitabilities-of-aging-how-inevitable-are-they/
Speculative investors have their fill of TRL shares, thanks to the 2 recent financings. The next uptick will be news driven and will attract more conservative investors who would rather pay more for additional certainty.
Safety results for Tefina will not be reported until a Phase III is completed in several years! Expectations are promising because Tefina uses an extremely micro dose of Testosterone, on demand only, and as Yep already said, tests have already shown T levels return to baseline within 24 hours. But I am wasting my breath here!
Tgtbtroi & spockdr remind me of the story of the lady whose car would not start on the Decarie Expressway. She walked back to the man in the car behind her and asked if he would try to start her car for her. She said "I'll stay back here in your car and honk for you."